Which Mendelian variants matter most for Rhodesian Ridgebacks?
The Mendelian-disease table above lists variants screened in 323 Rhodesian Ridgebacks (Donner 2023). Two matter most by impact, and the first one is urgent to understand.
Dilated Cardiomyopathy risk factor (TTN, PDK4-related)
Dilated cardiomyopathy in Rhodesian Ridgebacks is an autosomal-dominant-with-incomplete-penetrance heart condition. The TTN variant (flagged as PDK4-related from its discovery in the Doberman Pinscher) predisposes to enlarged heart chambers and reduced contractility. This is a high-severity condition that can cause sudden death. 21.8% of Ridgebacks in the Donner cohort carry the variant (n=323). One in five.
This is the single most important genetic number for the breed. Not every dog with one copy develops clinical cardiomyopathy, the incomplete penetrance means some carriers remain asymptomatic, but the risk is real and the stakes are high. Testing is available. Affected dogs are managed with cardiac medications under veterinary supervision; specific protocols follow ACVIM consensus guidelines (Keene et al. 2019, JVIM 33:1763-1804). Annual echocardiography is standard screening for at-risk dogs.
Cystinuria Type I-A (SLC3A1)
Cystinuria Type I-A in Rhodesian Ridgebacks is an autosomal-recessive condition caused by a variant in SLC3A1. The condition causes excess urinary cystine excretion and predisposes to bladder and kidney stones. 5.9% of Ridgebacks carry one copy (n=323). Affected dogs are managed with diet (low-protein, alkalinizing) and monitoring.
Testing is available from most commercial canine DNA labs.
Degenerative Myelopathy (DM)
Degenerative myelopathy in Rhodesian Ridgebacks is an autosomal-recessive-with-incomplete-penetrance neurological condition. The condition causes progressive spinal-cord degeneration, typically beginning in the rear limbs and advancing toward the front. Affected dogs lose mobility over months to years. 5.4% of Ridgebacks carry one copy (n=323).
Not every dog with two copies of the variant develops clinical signs, which is why the inheritance is incomplete penetrance. The condition typically emerges in mid to late life in dogs with two copies of the SOD1 variant (Zeng et al. 2014, J Vet Intern Med 28:1355-1361). Testing is available and is recommended for breeding stock.
How should I test my Rhodesian Ridgeback?
A breed-specific panel from a CLIA-accredited lab is the highest-yield path. The minimum useful set for Ridgebacks is TTN (dilated cardiomyopathy risk factor, PDK4-related), SLC3A1 (cystinuria), and SOD1 (DM). Testing for the lower-frequency variants (EIC, JME, CMR1, Bald Thigh Syndrome) is available but less urgent unless you have family history.
What should I feed a Rhodesian Ridgeback?
Feeding a Ridgeback well means feeding around the breed’s known genetic vulnerabilities. The TTN-variant dilated cardiomyopathy carrier frequency of 21.8% shapes the nutrition priority: cardiac support is the first concern.
Taurine status and grain-free formulations warrant the same caution as in other breeds. The FDA’s 2018 advisory flagged a diet-associated cardiac signal in certain grain-free formulations. While that signal was most prominent in Goldens, the biology applies across breeds. For a Ridgeback carrying or at risk for TTN-variant cardiomyopathy, a grain-inclusive, taurine-supplemented adult formulation from a manufacturer that runs feeding trials is the conservative default. Taurine levels of 0.1% to 0.3% by dry matter are standard; ask the manufacturer for their taurine concentration if cardiac risk is present.
Joint care is secondary but real. The OFA reports hip dysplasia rates for evaluated Ridgebacks at ofa.org/diseases/hip-dysplasia, and the breed’s size means early-life bone development needs precision. A large-breed puppy formulation with controlled calcium and a calcium-to-phosphorus ratio between 1.1:1 and 2:1 supports skeletal development without over-supplementation (NRC 2006). Adult-life weight management protects the spine in dogs at DM risk.
Protein and amino acid balance matter for neurological support. Dogs at risk for degenerative myelopathy benefit from complete amino acid profiles with adequate methionine and cysteine. A high-quality protein source (animal-based rather than plant-based as the primary protein) is a reasonable choice here, though the evidence for prevention of DM onset is not yet definitive.
The breed’s cystinuria carriers are managed with low-protein, alkalinizing diets if they form stones; this is individualized management, not a breed-wide rule. Consult your veterinarian if a Ridgeback has a history of urinary calculi.
What we don’t know
The relationship between the TTN variant and clinical cardiomyopathy in Ridgebacks is incompletely penetrant, which means we do not yet know which of the 21.8% of carriers will become symptomatic and which will remain asymptomatic throughout life. The penetrance evidence from Donner 2023 has not yet quantified this split in Ridgebacks specifically.
The exercise-induced collapse variant shows zero phenotype confirmation in the Donner cohort (0/2 at-risk dogs), so the clinical significance of this variant in Ridgebacks is still uncertain. Similarly, the CMR1 retinal variant shows zero phenotype confirmation (0/1 at-risk dog). These may be important variants or incidental findings; we do not yet have enough clinical data to say.
The Donner cohort for Ridgebacks is 323 dogs, which is smaller than some of the larger breeds in the study. Rare variants may not be captured, and the confidence intervals around the carrier frequencies are wider than in the largest breeds.
Frequently asked questions about Rhodesian Ridgebacks
What is the most common genetic disease in Rhodesian Ridgebacks? Dilated cardiomyopathy risk, driven by the TTN variant (PDK4-related). 21.8% of Ridgebacks in the Donner cohort carry the variant (Donner 2023, n=323). Not every carrier develops clinical disease, but the risk is real and warrants screening.
How long do Rhodesian Ridgebacks live? The breed’s median lifespan is often cited as approximately 10 to 12 years by breed clubs, consistent with large-breed longevity (Rhodesian Ridgeback Club of the United States, rhrc.org). Individual dogs show substantial variation based on genetics, diet, and management of any cardiac or neurological conditions.
Should I do a DNA test on my Rhodesian Ridgeback? For breeding stock, yes. The breed-specific health committee recommends testing for TTN (dilated cardiomyopathy risk factor), SLC3A1 (cystinuria), and SOD1 (DM). If you are buying a Ridgeback puppy, ask the breeder for test results on both parents.
Are Rhodesian Ridgebacks prone to heart disease? Yes. The TTN variant (PDK4-related) is present in roughly one in five Ridgebacks (21.8%). Regular cardiac screening by a veterinarian is recommended, especially as dogs age. Discuss with your vet whether echocardiography is warranted.
What should I feed a Rhodesian Ridgeback? A grain-inclusive, taurine-supplemented large-breed adult formulation from a manufacturer that runs feeding trials is the conservative default, especially for dogs at cardiac risk. Avoid grain-free diets unless your vet recommends one for specific gastrointestinal disease. Puppy formulations should maintain calcium-to-phosphorus ratios between 1.1:1 and 2:1 (NRC 2006).
Are Rhodesian Ridgebacks good family dogs? Yes. The breed is stable and tolerant with children and other dogs. They are single-prey-drive hunters originally, so socialization with smaller pets should start early. Their size and strength mean supervision with small children is important.
Do Rhodesian Ridgebacks have a ridge on their back? Yes. The ridge is the breed’s signature trait, a stripe of hair running forward along the spine. It is a dominant trait and is present in nearly all Ridgebacks. The ridge itself is a cosmetic trait, though a related condition called dermoid sinus can occur along the ridge line and should be checked by a veterinarian in puppies.
What health screening should I do before buying a Rhodesian Ridgeback puppy? Ask the breeder for: (1) TTN (DCM risk factor) genetic test results on both parents; (2) SLC3A1 and SOD1 (DM) genetic test results; (3) OFA hip and elbow evaluations on both parents; (4) cardiac screening by echocardiography if either parent carries the TTN variant. Request documentation from a CLIA-accredited lab for genetic tests.